Please enable JavaScript to continue using this application.

Compare $ARDX vs $CRVS | Chartloom

Compare

$ARDX vs $CRVS

Ardelyx Inc · Corvus Pharmaceuticals Inc

ARDX

Ardelyx Inc

CRVS

Corvus Pharmaceuticals Inc

Compare $ARDX vs $CRVS

Comparing Ardelyx Inc and Corvus Pharmaceuticals Inc

ARDXArdelyx Inc

CRVSCorvus Pharmaceuticals Inc

ARDXArdelyx Inc

Market cap

$810M

P/E (TTM)

—

Forward P/E (NTM)

688.58x

Forward P/S (NTM)

1.51x

Rev growth (TTM)

16.8%

YTD performance

-46.7%

52W performance

-35.2%

FCF yield

-2.2%

CRVSCorvus Pharmaceuticals Inc

Market cap

$885M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

43.7%

52W performance

50.3%

FCF yield

-5.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ARDX

CRVS

Detailed metrics comparison

ARDX

Ardelyx Inc

CRVS

Corvus Pharmaceuticals Inc

Market Cap

ARDX$810M

CRVS$885M

Enterprise Value

ARDX$965M

CRVS$866M

Price

ARDX$3.28

CRVS$10.52

P/E Ratio

ARDXN/A

CRVSN/A

P/S Ratio

ARDX1.80x

CRVS0.00x

EV/Sales

ARDX2.14x

CRVS0.00x

EV/EBITDA

ARDX454.80x

CRVS0.00x

P/B Ratio

ARDX5.59x

CRVS4.07x

P/FCF Ratio

ARDXN/A

CRVSN/A

EV/FCF

ARDX-53.85x

CRVS-19.14x

PEG Ratio

ARDXN/A

CRVSN/A

Forward P/E (NTM)

ARDX688.58x

CRVSN/A

Forward P/S (NTM)

ARDX1.51x

CRVSN/A

Revenue (TTM)

ARDX$451M

CRVS$0

Revenue Growth (YoY)

ARDX16.8%

CRVSN/A

Forward Rev Growth

ARDX27.5%

CRVS1220.6%

Gross Margin (TTM)

ARDX94.4%

CRVS0.0%

Operating Margin (TTM)

ARDX0.0%

CRVS0.0%

EBITDA Margin (TTM)

ARDX-7.1%

CRVS0.0%

Net Margin (TTM)

ARDX-12.4%

CRVS0.0%

FCF Margin (TTM)

ARDX-4.0%

CRVSN/A

Net Income (TTM)

ARDX$-56M

CRVS$-54M

FCF (TTM)

ARDX$-18M

CRVS$-45M

EPS (TTM)

ARDX-$0.22

CRVS-$0.59

ROE (TTM)

ARDX-3600.0%

CRVS-3615.0%

ROA (TTM)

ARDX-1077.0%

CRVS-3362.0%

ROIC (TTM)

ARDX-1506.0%

CRVS-3615.0%

Cash

ARDX$97M

CRVS$19M

Debt

ARDX$252M

CRVS$0

Net Cash/Debt

ARDX$-155M

CRVS$19M

Current Ratio (TTM)

ARDX3.34x

CRVS16.16x

Quick Ratio (TTM)

ARDX2.89x

CRVS15.92x

Debt/Equity (TTM)

ARDX1.69x

CRVS0.00x

Debt/Assets (TTM)

ARDX0.0%

CRVS0.0%

Interest Coverage (TTM)

ARDXN/A

CRVSN/A

Net Debt/EBITDA (TTM)

ARDX0.00x

CRVS0.00x

Beta

ARDX0.72

CRVS1.59

52W Performance

ARDX-35.2%

CRVS50.3%

YTD Performance

ARDX-46.7%

CRVS43.7%

% from 52W High

ARDX-61.0%

CRVS-61.0%

% from 52W Low

ARDX3.1%

CRVS64.6%

Asset Turnover (TTM)

ARDX0.87x

CRVS0.00x

FCF Yield (TTM)

ARDX-2.2%

CRVS-5.1%

Earnings Yield (TTM)

ARDX-6.9%

CRVS-6.1%

Dividend Yield (TTM)

ARDXN/A

CRVSN/A

Rule of 40

ARDX12.8

CRVS0.0

EV/GP/RG

ARDX0.10

CRVSN/A

Ticker research

View ARDX research View CRVS research

Metric	ARDX Ardelyx Inc	CRVS Corvus Pharmaceuticals Inc
Market & Valuation
Market Cap	$810M	$885M
Enterprise Value	$965M	$866M
Price	$3.28	$10.52
P/E Ratio	N/A	N/A
P/S Ratio	1.80x	0.00x
EV/Sales	2.14x	0.00x
EV/EBITDA	454.80x	0.00x
P/B Ratio	5.59x	4.07x
P/FCF Ratio	N/A	N/A
EV/FCF	-53.85x	-19.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	688.58x	N/A
Forward P/S (NTM)	1.51x	N/A
Revenue & Growth
Revenue (TTM)	$451M	$0
Revenue Growth (YoY)	16.8%	N/A
Forward Rev Growth	27.5%	1220.6%
Profitability
Gross Margin (TTM)	94.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-7.1%	0.0%
Net Margin (TTM)	-12.4%	0.0%
FCF Margin (TTM)	-4.0%	N/A
Net Income (TTM)	$-56M	$-54M
FCF (TTM)	$-18M	$-45M
EPS (TTM)	-$0.22	-$0.59
ROE (TTM)	-3600.0%	-3615.0%
ROA (TTM)	-1077.0%	-3362.0%
ROIC (TTM)	-1506.0%	-3615.0%
Financial Health
Cash	$97M	$19M
Debt	$252M	$0
Net Cash/Debt	$-155M	$19M
Current Ratio (TTM)	3.34x	16.16x
Quick Ratio (TTM)	2.89x	15.92x
Debt/Equity (TTM)	1.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	1.59
52W Performance	-35.2%	50.3%
YTD Performance	-46.7%	43.7%
% from 52W High	-61.0%	-61.0%
% from 52W Low	3.1%	64.6%
Efficiency & Yields
Asset Turnover (TTM)	0.87x	0.00x
FCF Yield (TTM)	-2.2%	-5.1%
Earnings Yield (TTM)	-6.9%	-6.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	12.8	0.0
EV/GP/RG	0.10	N/A
Ticker research	View ARDX research	View CRVS research

Valuation

P/S Ratio

CRVS

0.00x

ARDX

1.80x

EV/FCF

ARDX

-53.85x

CRVS

-19.14x

Growth & revenue

Revenue Growth TTM

ARDX

16.8%

Forward Revenue Growth

CRVS

1220.6%

ARDX

27.5%

Profitability & performance

Gross Margin

ARDX

94.4%

CRVS

0.0%

ROE

ARDX

-3600.0%

CRVS

-3615.0%

FCF Yield %

ARDX

-2.2%

CRVS

-5.1%

52-Week Performance

CRVS

50.3%

ARDX

-35.2%

Detailed metrics comparison

ARDX

Ardelyx Inc

CRVS

Corvus Pharmaceuticals Inc

Market Cap

ARDX$810M

CRVS$885M

Enterprise Value

ARDX$965M

CRVS$866M

Price

ARDX$3.28

CRVS$10.52

P/E Ratio

ARDXN/A

CRVSN/A

P/S Ratio

ARDX1.80x

CRVS0.00x

EV/Sales

ARDX2.14x

CRVS0.00x

EV/EBITDA

ARDX454.80x

CRVS0.00x

P/B Ratio

ARDX5.59x

CRVS4.07x

P/FCF Ratio

ARDXN/A

CRVSN/A

EV/FCF

ARDX-53.85x

CRVS-19.14x

PEG Ratio

ARDXN/A

CRVSN/A

Forward P/E (NTM)

ARDX688.58x

CRVSN/A

Forward P/S (NTM)

ARDX1.51x

CRVSN/A

Revenue (TTM)

ARDX$451M

CRVS$0

Revenue Growth (YoY)

ARDX16.8%

CRVSN/A

Forward Rev Growth

ARDX27.5%

CRVS1220.6%

Gross Margin (TTM)

ARDX94.4%

CRVS0.0%

Operating Margin (TTM)

ARDX0.0%

CRVS0.0%

EBITDA Margin (TTM)

ARDX-7.1%

CRVS0.0%

Net Margin (TTM)

ARDX-12.4%

CRVS0.0%

FCF Margin (TTM)

ARDX-4.0%

CRVSN/A

Net Income (TTM)

ARDX$-56M

CRVS$-54M

FCF (TTM)

ARDX$-18M

CRVS$-45M

EPS (TTM)

ARDX-$0.22

CRVS-$0.59

ROE (TTM)

ARDX-3600.0%

CRVS-3615.0%

ROA (TTM)

ARDX-1077.0%

CRVS-3362.0%

ROIC (TTM)

ARDX-1506.0%

CRVS-3615.0%

Cash

ARDX$97M

CRVS$19M

Debt

ARDX$252M

CRVS$0

Net Cash/Debt

ARDX$-155M

CRVS$19M

Current Ratio (TTM)

ARDX3.34x

CRVS16.16x

Quick Ratio (TTM)

ARDX2.89x

CRVS15.92x

Debt/Equity (TTM)

ARDX1.69x

CRVS0.00x

Debt/Assets (TTM)

ARDX0.0%

CRVS0.0%

Interest Coverage (TTM)

ARDXN/A

CRVSN/A

Net Debt/EBITDA (TTM)

ARDX0.00x

CRVS0.00x

Beta

ARDX0.72

CRVS1.59

52W Performance

ARDX-35.2%

CRVS50.3%

YTD Performance

ARDX-46.7%

CRVS43.7%

% from 52W High

ARDX-61.0%

CRVS-61.0%

% from 52W Low

ARDX3.1%

CRVS64.6%

Asset Turnover (TTM)

ARDX0.87x

CRVS0.00x

FCF Yield (TTM)

ARDX-2.2%

CRVS-5.1%

Earnings Yield (TTM)

ARDX-6.9%

CRVS-6.1%

Dividend Yield (TTM)

ARDXN/A

CRVSN/A

Rule of 40

ARDX12.8

CRVS0.0

EV/GP/RG

ARDX0.10

CRVSN/A

Ticker research

View ARDX research View CRVS research

Metric	ARDX Ardelyx Inc	CRVS Corvus Pharmaceuticals Inc
Market & Valuation
Market Cap	$810M	$885M
Enterprise Value	$965M	$866M
Price	$3.28	$10.52
P/E Ratio	N/A	N/A
P/S Ratio	1.80x	0.00x
EV/Sales	2.14x	0.00x
EV/EBITDA	454.80x	0.00x
P/B Ratio	5.59x	4.07x
P/FCF Ratio	N/A	N/A
EV/FCF	-53.85x	-19.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	688.58x	N/A
Forward P/S (NTM)	1.51x	N/A
Revenue & Growth
Revenue (TTM)	$451M	$0
Revenue Growth (YoY)	16.8%	N/A
Forward Rev Growth	27.5%	1220.6%
Profitability
Gross Margin (TTM)	94.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-7.1%	0.0%
Net Margin (TTM)	-12.4%	0.0%
FCF Margin (TTM)	-4.0%	N/A
Net Income (TTM)	$-56M	$-54M
FCF (TTM)	$-18M	$-45M
EPS (TTM)	-$0.22	-$0.59
ROE (TTM)	-3600.0%	-3615.0%
ROA (TTM)	-1077.0%	-3362.0%
ROIC (TTM)	-1506.0%	-3615.0%
Financial Health
Cash	$97M	$19M
Debt	$252M	$0
Net Cash/Debt	$-155M	$19M
Current Ratio (TTM)	3.34x	16.16x
Quick Ratio (TTM)	2.89x	15.92x
Debt/Equity (TTM)	1.69x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.72	1.59
52W Performance	-35.2%	50.3%
YTD Performance	-46.7%	43.7%
% from 52W High	-61.0%	-61.0%
% from 52W Low	3.1%	64.6%
Efficiency & Yields
Asset Turnover (TTM)	0.87x	0.00x
FCF Yield (TTM)	-2.2%	-5.1%
Earnings Yield (TTM)	-6.9%	-6.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	12.8	0.0
EV/GP/RG	0.10	N/A
Ticker research	View ARDX research	View CRVS research